Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) Securities Fraud Class Action

Case Background:
This is a federal securities fraud class action lawsuit on behalf of those who purchased or otherwise acquired Maravai LifeSciences Holdings, Inc. (“Maravai”) (NASDAQ: MRVI) securities between August 7, 2024 and February 24, 2025, inclusive (the “Class Period”).

The complaint alleges that, throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) Maravai lacked adequate internal controls over financial reporting related to revenue recognition; (2) as a result, Maravai inaccurately recognized revenue on certain transactions during fiscal 2024; (3) Maravai’s goodwill was overstated; and (4) as a result of the foregoing, Defendants’ positive statements about the company’s business, operations, and prospects were materially false and/or misleading and/or lacked a reasonable basis at all relevant times.

Current Status of Case:
On January 15, 2026, the Court granted Defendants’ Motion to Dismiss the Amended Complaint. This action has concluded.

If you wish to discuss this action or have any questions, please contact Kessler Topaz Meltzer & Check, LLP: Jon Naji, Esq. (484) 270-1453; toll-free at (844) 887-9500; or via e-mail at [email protected]. If you would like additional information about the suit, please click on the link “Submit Your Information” above and fill out the form as promptly as possible.